Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)
Funding Agency:
- National Institutes of Health
Many major biomedical research problems are best addressed with a multidisciplinary approach that bridges life sciences and physical sciences. Principles and techniques in quantitative sciences such as physics, mathematics, chemistry, computer sciences, and engineering are increasingly applied to enable and advance biomedical research. Bioengineering approaches integrate principles from diverse technical and biomedical fields, and the resulting multi-disciplinary research provides new understanding, innovative technologies, and new products that improve basic knowledge, human health, and quality of life. This FOA seeks to encourage collaborations among investigators in the fields of quantitative science and physical science with biomedical researchers to catalyze the development of innovative bioengineering approaches to solve important problems in biomedical research, translational research, clinical investigations, and medical practice.
Significant projects may include, but are not limited to: development, validation, and translation of promising modalities for the disease continuum, including tools for risk prediction, screening, prevention, detection, diagnosis, disease progression, intervention, monitoring treatment response, prognosis, or survival; development of quantitative, predictive models of complex biological systems; integration and optimization of technologies that significantly increase sensitivity, specificity, positive predictive value, negative predictive value, efficiency, or throughput of analysis to address unsolved biological or medical questions; in vitro and in vivo models, cell/tissue culture systems and organoids that closely mimic physiological conditions and allow mechanistic studies or engineering and testing of delivery systems, molecules/cells/tissues for therapeutic purposes, therapeutics, implants, and prosthetics that may improve treatment and healthcare.
Innovation in this biomedical engineering FOA has a broad definition that includes development of new methods, ideas, or tools, integration of existing components into new combinations that deliver new and/or greater capabilities, new efficiencies, and/or greater effects. Overall impact of these advances may include improving our understanding of molecular mechanisms, reducing disparities in access to care, promoting wellness and independent living, increasing access to and utility of technologies to improve quality of life, reducing the cost and complexity of procedures, and/or increasing throughput, sensitivity, and specificity of diagnostic tests.
A project must clearly serve the mission of one or more of the NIH Institutes or Centers participating in this FOA. Investigators are encouraged to contact the designated Scientific/Research contacts for individual institute focus areas that will be supported. Applicants who seek to establish proof-of-concept are encouraged to respond to the Exploratory Bioengineering Research Grant (EBRG) FOA [https://grants.nih.gov/grants/guide/pa-files/par-22-091.html].
Application budgets are not limited but need to reflect the actual needs of the proposed project.
October 31, 2022, February 05, 2023, June 05, 2023
Rao Divi, Ph.D., National Cancer Institute (NCI), Telephone: 240-276-6913, Email: divir@mail.nih.gov